Every year, approximately 500 women are diagnosed with ovarian cancer in Germany, typically around the age of 63. Thanks to advanced treatment methods, survival rates have significantly improved, predominantly through personalized approaches and genetic analyses.
Understanding Genetic Risks
Several risk factors for ovarian cancer have been identified by science. While the BRCA1 and BRCA2 mutations are well-known, new research continues to unveil additional insights. A Swedish registry study by Moberg et al. (2026) indicates that women with endometriosis face an increased risk of both ovarian and breast cancer, particularly in the year following their endometriosis diagnosis.
The standard treatment protocol traditionally involves a two-step process: surgical removal of the tumor tissue followed by platinum-based chemotherapy. Today, this regimen is frequently complemented by PARP inhibitors and antibody therapies to enhance efficacy.
New Approaches to Platinum Resistance
One of the most pressing challenges in treating ovarian cancer is platinum resistance. The Phase 1b/2 VIRO-15 study has shown promising results in this realm. The primed immunochemotherapy Olvi-Vec was able to restore platinum sensitivity in patients with platinum-resistant or refractory ovarian cancer. Currently, a Phase 3 study (OnPrime/GOG-3076) is underway to validate these findings.
Long-term treatment strategies are also evolving. An analysis published in JAMA Oncology reveals that for patients demonstrating exceptional responses, maintaining PARP inhibitors can be safely ceased after 7.5 years, provided the progression-free survival rate is at least 88.8 percent.
Immunotherapies for Lynch Syndrome and MSI-high Cases
Immunotherapies have proven effective for women with Lynch Syndrome or high microsatellite instability (MSI-high). In some exceptional cases, this personalized treatment strategy has even resulted in complete tumor remission.
Prevention through Diagnostics – A Word of Caution
Genetic diagnostics are becoming increasingly crucial. For instance, countries like Montenegro are planning to implement free BRCA testing and preventive mastectomies for women at high risk to bolster early detection efforts.
However, meticulous care is required in the diagnostic process. An incident at the Kepler University Hospital in Linz exemplifies these risks: a contaminated tissue sample led to a misdiagnosis of cancer in a healthy patient, resulting in unnecessary surgical removal of her uterus and ovaries, which the clinic subsequently acknowledged as their responsibility.
The Promise of mRNA Vaccines
Medical professionals are also exploring the further development of mRNA vaccines. A review published in The Lancet substantiates the safety and high efficacy of this technology for infectious diseases, while researchers see significant potential for its use as cancer vaccines, particularly for bladder and skin cancers.
Germany’s Expanding Research Landscape
The BeOne Medicines initiative has increased its number of studies in Europe by 180% between 2019 and 2023. Collaborating with iuvando Health, the goal is to expand the study offerings in Germany by an additional 35%. Currently, over 150 patients are enrolled across 70 German centers as part of 14 active studies, with the objective of translating scientific findings into clinical practice more swiftly.
